Paroxetine Studies
Select the study ID number to view the trial summary
| Study ID | Phase | Title |
| EPIP083 (Preliminary report) | - | EPIDEMIOLOGY STUDY: Preliminary Report on Bupropion in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation. |
| EPIP083 (Final report) | - | EPIDEMIOLOGY STUDY: Final Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation. |
| EPIP083 (Updated Preliminary report) | - | EPIDEMIOLOGY STUDY: Updated Preliminary Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation. |
| EPI40404 (Follow-up up to EPIP083) | - | EPIDEMIOLOGY STUDY: Paroxetine in the First Trimester and the Prevalence of Congenital Malformations (Follow-up to Epidemiology Study: Final Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformations). |
| *063 | IV | A double blind randomised trial comparing the effects on sleep of paroxetine 30mg daily and amitriptyline 150mg daily in patients with major depression. |
| 029060/1/CPMS-086 | IV | A Controlled Double-blind Randomised Parallel Group Study Comparing the Effects of Paroxetine and Maprotiline in the Treatment of Out-Patients with Major and Minor Depression |
| 1991-Dataset | IV | Analysis of suicide attempts in paroxetine clinical trials for the adult clinical trial population (1991 Dataset). |
| 2001-Dataset | IV | Results of the investigation of suicide attempts and suicidal thinking identified by ‘narrow’ and ‘broad’ definition algorithms in the adult clinical trial population (2001 Dataset). |
| 2003-Pediatric-Review | IV | Paediatric-only clinical trials results of investigation of suicide attempts and “possibly suicide-related” events (2003 Paediatric Review). |
| 2006-Analysis | IV | Paroxetine Adult Suicidality Analysis (2006 Dataset) |
| 29060/097 | IV | ECT and paroxetine/imipramine combination treatment in depressive states. A clinical study of the safety of co-administration of ECT and paroxetine or imipramine, and relapse prevention in the maintenance phase. |
| 29060/332 | IV | A Double-Blind, Multicentre Study to Assess the Efficacy and Tolerability of Paroxetine and Amitriptyline in Patients With a Mild, Moderate, or Severe Depressive Episode Associated With Rheumatoid Arthritis |
| 29060/358 | IV | Comparative study of paroxetine and mianserin in depression of the elderly: efficacy, tolerance, serotonin dependence. |
| 29060/395 | IV | Double-blind, randomised study to compare the effects of paroxetine and amitriptyline on driving ability and psychomotor performance in patients with mild to moderate depression treated for at least 4 weeks |
| 29060/397 | IV | A double-blind multicentre study to assess the tolerability and efficacy of paroxetine compared with amitriptyline in the treatment of depressed patients in general practice |
| 29060/406 | IV | A Double-Blind, Long-Term Extension Study for Patients Previously Participating in Protocol 29060/131 |
| 29060/409 | IV | A comparative, controlled double blind, double dummy study about the efficacy and safety of paroxetine vs imipramine in ambulatory patients with major depression |
| 29060/436 | IV | Safety Evaluation of Paroxetine in Elderly Depressed Patients |
| 29060/442 | IV | A multicentre, randomised, double-blind study to compare paroxetine versus placebo in the treatment of double depression. |
| 29060/516 | IV | A post-marketing surveillance to monitor the safety of Seroxat (paroxetine hydrochloride) administered in Korean subjects according to the prescribing information. |
| 29060/523 | IV | Open prospective study to evaluate the efficacy and safety of paroxetine in the treatment of Panic Disorder and Obsessive-Compulsive Disorder |
| 29060/524 | IV | An open multicentre prospective study to compare antidepressive activity of paroxetine in monotherapy and paroxetine combined with pindolol in the treatment of depression |
| 29060/622 | IV | Open study to evaluate the efficacy and safety of paroxetine in the treatment of minor depression. |
| 29060/681 | IV | Open study to evaluate the efficacy and the safety of paroxetine in the treatment of depression associated with a physical disorders |
| 29060/785 | IV | A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of Major Depressive Disorder with anxiety |
| 29060/810 | IV | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy and Safety of Paroxetine Controlled Release (12.5 and 25 mg/day) Versus Placebo in Patients with Major Depressive Disorder |
| 999910/126 | IV | A placebo-controlled, randomised, double-blinded, parallel group study in healthy volunteers to assess the effects of paroxetine on ejaculation and accompanying neurohumoral parameters. |
| Article-31 | IV | Article 31 referral analyses of GSK’s clinical trial data to evaluate the risk of suicide, suicidal thoughts and behaviours, and self-harm, with particular attention to potential risk factors including age and gender |
| BRL 029060/621 | IV | A randomized, double-blind, placebo-controlled trial of intermittent treatment with paroxetine 10mg/day and 20mg/day versus placebo in Canadian women with Premenstrual Dysphoric Disorder |
| BRL 29060/Paroxetine/368 | IV | Belgian Paroxetine Experience: An open-label study evaluating the efficacy and safety of paroxetine in depressed patients treated by Belgian psychiatrists and general practitioners |
| BRL-29060/874 | IV | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed with Major Depressive Disorder |
| BRL29060A/104228 | IV | Post-marketing clinical study of Paxil® Tablet in patients with depression or depressive state - A study on combination of Paxil® Tablet and benzodiazepines - |
| EPI40297 | IV | Paroxetine, SSRI Use and the Risk of Suicidal Behaviour |
| MY-0144/BRL 29060/1/CPMS-135 (PAR 135) | IV | A Comparative Double-Blind Study of Paroxetine and Fluoxetine in the Treatment of Depression in Out-Patients |
| PAR 029060/402 | IV | A double-blind, multicentre, parallel group study of paroxetine and amitriptyline in the treatment of patients with depression associated with breast cancer |
| PAR 029060/833 | IV | An Open-label Study Assessing PAXIL CR (paroxetine CR) in Patients with Major Depressive Disorder Who Discontinued Treatment with Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/Norepinephrine Reuptake Inhibitor Due to Intolerability |
| PAR 029060-382 | IV | A Randomized, Double-Blind, Comparison of Paroxetine and Placebo in the Treatment of Generalized Social Phobia |
| PAR 29060. 331 | IV | Paroxetine in Depressed Patients with Ischemic Heart Disease- A Randomized Safety Study |
| PAR 29060.189 | IV | A Double-Blind Randomized Study to Provide Safety Information on Switching Fluoxetine-Treated Patients to Paroxetine without an Intervening Washout Period |
| PAR 29060.239 | IV | A Randomized, Comparative Study of Paroxetine in the Treatment of Depression as Used in a Clinical Practice Setting |
| PAR 352 | IV | A Double-Blind, Placebo-Controlled, Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression |
| SB 29060/536 | IV | A Randomized, Open Trial to Compare Patient Medication Compliance, Efficacy and Quality of Life in Patients Receiving Paroxetine, (20 mg od) Dispensed in Bottles Compared with Paroxetine, (20 mg od) Dispensed in Blister Packaging |
| SX12003 | IV | Treatment of depressed and/or anxiety subjects with paroxetine in the primary care. |
| Taiwan-PAR | IV | Paroxetine in the Treatment of Chinese Patients with Depressive Episodes – A Double-blind randomized Comparison with Imipramine |
| WEUSRTP2280 | IV | First Trimester Paroxetine Use and the Prevalence of Congenital, Specifically Cardiac, Malformations: Systematic Review and Meta-Analysis of Epidemiological Data |
| WEUSRTP810 | IV | EPIDEMIOLOGY STUDY: First Trimester Exposure to Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Birth Defects |
| 029060/092 | III | A double-blind, between patient, multicentre study comparing the efficacy, tolerability and effects on cognitive function of paroxetine with those of lofepramine in depressed patients in general practice |
| 29060/056/UK | III | A double-blind, between patient, multicentre study in general practice comparing the efficacy and tolerability of paroxetine with those of dothiepin in the treatment of elderly depressed patients |
| 29060/081/CH/001 (Formerly PAR MDCH/29060/III/081/3/Van/Kasas) | III | An Open Pharmacokinetic and Pharmacodynamic Study of Paroxetine (20mg, 30mg, or 40mg daily) in the Treatment of Major Depressive Disorder (DSM III) |
| 29060/087 | III | A double-blind, randomised, multicentre study comparing paroxetine 20mg daily versus fluoxetine 20mg daily in the treatment of adults with major depression with regard to antidepressant efficacy, tolerance and anxiolytic effect. |
| 29060/103 | III | A Double-Blind, Multicentre Study Comparing the Efficacy, Tolerability and Effects on Cognitive Function of Paroxetine With Those of Lofepramine in Elderly Depressed Hospital In- or Out-Patients |
| 29060/108 | III | Paroxetine in Panic Disorder. A double-blind, randomised, multi-centre, placebo-controlled study of paroxetine in combination with psychotherapy in the treatment of patients with panic disorder (DSM-III-R). |
| 29060/131 | III | A Double-Blind, Randomized, Multicentre Comparison of Paroxetine and Fluoxetine in the Treatment of Patients With Major Depression With Regard to Antidepressant Efficacy, Tolerance and Anxiolytic Effect |
| 29060/134 | III | A randomized, double-blind, controlled study of paroxetine and fluoxetine in the treatment of patients with major depression with associated anxiety. |
| 29060/298 | III | A double-blind study comparing the efficacy and tolerability of paroxetine and placebo in hospital out-patients with depressive symptoms associated with chronic back pain. |
| 29060/299 | III | A Double-Blind Study Comparing The Efficacy and Tolerability of Paroxetine and Amitriptyline In Patients With Severe Depression. |
| 29060/326 | III | A double-blind, randomised multi centre study to assess the safety and tolerability of paroxetine and amitriptyline in depressed subjects stabilised on lithium treatment |
| 29060/353 | III | A Ten-Week, Single-Blind, Multicentre Study Evaluating the Efficacy and Tolerability of Paroxetine vs. Desipramine in the Treatment of Outpatients with Major Depression According to DSM-III-R |
| 29060/421 | III | Paroxetine and Fluoxetine effects on mood and cognitive function in depressed nondemented elderly patients |
| 29060/433 | III | Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor |
| 29060/448 | III | A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression |
| 29060/449 | III | A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression |
| 29060/487 | III | A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression in Elderly Patients |
| 29060/494 | III | A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Modified-Release Paroxetine in the Treatment of Panic Disorder |
| 29060/495 | III | A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder |
| 29060/497 | III | A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder |
| 29060/509 | III | An open, non-comparative multi-centre study to assess the efficacy and tolerability of paroxetine 20mg daily in the treatment of depression and depression associated with anxiety |
| 29060/512 | III | A multi-centre, double-blind placebo-controlled study to investigate the effect of pindolol on the onset of antidepressant activity of paroxetine in the treatment of depression. |
| 29060/518 | III | A multi-centre, double-blind, double dummy, randomised controlled study to investigate the speed of onset, safety, efficacy and tolerability of paroxetine in combination with pindolol compared with dothiepin in the treatment of depression. |
| 29060/525 | III | A double blind, multicenter randomized drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of panic disorder. |
| 29060/526 | III | A double blind, multicenter, randomized, drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of obsessive compulsive disorder. |
| 29060/650 | III | A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder |
| 29060/658 | III | A Placebo-Controlled Study to Investigate the Efficacy of Intermittent and Continuous Treatment With Paroxetine in Patients With Premenstrual Dysphoric Disorder (PMDD) |
| 29060/677 | III | A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder |
| 29060/688 | III | A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder |
| 29060/689 | III | A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder |
| 29060/711 | III | A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies 29060/677, 688 or 689 |
| 29060/717 | III | A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder |
| 29060/730 | III | Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders |
| 29060/791 | III | A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients with Generalized Anxiety Disorder (GAD) |
| 29060/III/083/MC (PAR 083) | III | A Double-blind Comparative Multicentre Study of Paroxetine and Placebo in Preventing Depressive Episodes in Recurrent Major Depressive Disorders |
| BRL-029060/329 - continuation | III | A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression – Continuation Phase. |
| BRL-029060/329: Acute Phase | III | A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Acute Phase |
| BRL-029060/377 | III | A Double-blind, Multicentre Placebo-Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression. |
| BRL-029060/437 | III | A Double-blind, Placebo-controlled Study to Investigate the Effect of Pindolol on the Onset of Anti-depressant Activity of Paroxetine in the Treatment of Depression. |
| BRL-029060/453 | III | A 38-Week, Two Phase, Multi-center Study to Investigate the Safety and Effectiveness of paroxetine (10-60mg/day in the Treatment of Children and Adolescent Outpatients with Obsessive Compulsive Disorder (OCD) |
| BRL-029060/676 | III | A 16 Week Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Paroxetine in the Treatment of Children and Adolescents with Social Anxiety Disorder/Social Phobia. |
| BRL-029060/701 | III | A Randomized, Multi-center, 8-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) |
| BRL-029060/704 | III | A Randomized, Multi-center, 10-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Obsessive Compulsive Disorder |
| BRL-029060/715 | III | A Multi-center Study to Assess the Pharmacokinetics of Paroxetine Following Repeat-Dose Administration in Children and Adolescents with Obsessive Compulsive Disorder (OCD) and/or Depression |
| BRL-029060/716 | III | A Multi-center, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive Compulsive Disorder (OCD) |
| BRL-029060/CPMS- 116 | III | Paroxetine versus Placebo in the Treatment of Obsessive-Compulsive Disorder |
| BRL-029060/CPMS-126 | III | Long-term Treatment with Paroxetine of Outpatients with Obsessive-Compulsive Disorder. An Extension of the Fixed-Dose Study (Study 116). |
| BRL-029060/CPMS-190 | III | A Double-Blind, Comparative, Placebo-Controlled Trial of Paroxetine in the Prevention of Recurrent Depression |
| BRL-029060/CPMS-790 | III | A Double-blind, Placebo-controlled, Flexible-dose Study of Paroxetine CR in the Treatment of Patients with Social Anxiety Disorder |
| BRL-029060/RSD-101336/1/CPMS-641 | III | A Randomized, Double-Blind, Placebo Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Anxiety Disorder |
| BRL-29060/109 | III | A double-blind, short-term comparison of paroxetine and amitriptyline with a 12-month, rater-blind maintenance phase comparing paroxetine, amitriptyline and lithium in the prevention of depressive relapse in patients with major depression, recurrent. |
| BRL29060A/799 | III | Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A 52-Week, Non-Comparative, Uncontrolled Study for the Clinical Use Experience - |
| DFG/ 29060/III/86/121 & 126 (Study 262) | III | The Short Term Phase of an Open, Long Term Study of Paroxetine in Elderly Patients Suffering from Depression |
| DFG/29060/III/85/119 (PAR 261) | III | A Double-Blind, Comparative Study of Paroxetine and Clomipramine to Assess Efficacy and to Evaluate the Correlation Between Plasma Concentration and Effect |
| DFG/29060/III/86/124M (PAR 089) | III | A Double-Blind Study to Compare the Efficacy and Tolerability of Paroxetine with Imipramine in Depressed Patients: An Interim Report (A final report has not been prepared and is not expected for this study). |
| DGF/29060/III/86/123 (PAR88) | III | A Report on a Randomised, Double-Blind Comparative Study Including Evaluation of Effect Profiles and Correlations Between Plasma Concentration and Effect. |
| MDA/29060/III/87/2/3/4 (PAR 253) | III | An Open Pharmacokinetic and Pharmacodynamic Study of Paroxetine (20 – 50mg daily) in the Treatment of Major Depressive Disorder (DSM III) |
| MDB./29060/III/064/88/MC | III | A Double-blind Comparative Multicentre Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Depressed Patients |
| MDB/PAR/1/B/C/D/E M (PAR 256) | III | A Study of the Efficacy and Safety of Paroxetine in Subjects with Depression |
| MDB29060B/3/4/5/6/7/8/9M (PAR 257) | III | An Open Multicentre Study to Assess the Safety and Efficacy of Paroxetine in Patients with Depression |
| MDCH/29060/III/86/01/02 (PAR268) | III | A study to assess the efficacy and safety of paroxetine in patients with depression |
| MDED/29060/III/85/102/3/4/M (PAR 252) | III | A Multicentre Open Study to Investigate the Safety and Efficacy of Paroxetine in the Treatment of Depressed Patients |
| MDF/29060/III/067/3/BRION, MDF/29060/III/068/4/BRION, and MDF/29060/III/072/8/CLERC | III | A combined Report on the Clinical Aspects of Three Pharmacokinetic Studies of Paroxetine in the Treatment of Major Depressive Disorder (DSM III) |
| MDF/29060/III/070/88/MC | III | A multicentre, double-blind, parallel group, randomised dose study comparing the efficacy of paroxetine 20mg increasing to 30mg daily if there is insufficient response and clomipramine 60mg increasing to 75mg daily, in outpatients (age >60 years) with moderate depression according to feighner's criteria |
| MDUK/26090/III/83/007 | III | A Double-Blind Placebo Controlled Study to Compare Paroxetine with Maprotiline in the Treatment of Depression |
| MDUK/26090/III/83/012A(280) | III | An Investigation of the Efficacy and Tolerance of Paroxetine in an Open Study of Patients with Depression and Obsessive Compulsive Disorder |
| MDUK/29060/026 | III | An Interim Report to Evaluate the Efficacy and Tolerability of Paroxetine in the Treatment of Elderly Depressed Patients. A Double-blind Parallel Group Comparison with Mianserin |
| MDUK/29060/III/82/006 (PAR-274) | III | A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo |
| MDUK/29060/III/83/005 | III | An Investigation of the Pharmacokinetics of Paroxetine in Geriatric Patients with Depression |
| MDUK/29060/III/83/022 | III | A Study To Assess the Efficacy and Tolerance of Paroxetine In Patients with Depression by Double-Blind Comparison with Mianserin |
| MDUK/29060/III/84/004 Lavin (PAR 272) | III | A Comparison of the Efficacy and Tolerance of Paroxetine and Amitriptyline in the Treatment of Depression. A Double-Blind, Parallel Study |
| MDUK/29060/III/84/020 | III | An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Mianserin |
| MDUK/29060/III/85/027 | III | A Study to Assess the Effectiveness and Tolerance of Paroxetine in the Treatment of Depression by Double-Blind Comparison with Imipramine |
| MDUK/29060/III/85/028 | III | An Interim Report of a Study to Assess the Efficacy and Tolerability of Paroxetine in the Elderly, by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic |
| MDUK/29060/III/85/028A (PAR 184) | III | An Interim Report to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic |
| MDUK/29060/III/85/029 | III | An Assessment of the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic |
| MDUK/29060/III/85/030 | III | An Assessment of the Efficacy and Tolerability of Paroxetine by Double Blind Comparison with Mianserin in Patients Referred to a Psychiatric Clinic |
| MDUK/29060/III/85/034 | III | A Study to Assess the Efficacy and Tolerability of Paroxetine in Epileptic Patients with Depression |
| MDUK/29060/III/85/037 | III | The Short Term Phase of an Open, Long-Term, Safety and Tolerability Study of Paroxetine in Patients Suffering from Depression |
| MDUK/29060/III/85/038 | III | To Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double Blind Comparison with Mianserin |
| MDUK/29060/III/85/043 | III | An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Amitriptyline (A follow-up final report was not prepared and is not expected for this study). |
| MDUK/29060/III/85/044 (PAR 044) | III | A Double-blind Comparative Two-centre Study to Assess the Efficacy and Tolerability of Paroxetine (20mg vs 30mg) in Elderly Depressed Patients |
| MDUK/29060/III/86/025 | III | Double Blind Parallel Group Study Comparing Paroxetine 30mg daily, and Clomipramine 100mg daily, in Depressed In-Patients |
| MDUK/PAR/ 85/041 | III | A Study to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison of Morning and Evening Dosages |
| MY 1021/BRL 029060/1/CPMS/061 | III | A Double-blind Comparative Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Geriatric Patients with Major Depression |
| MY- 1028/BRL-029060/1/CPMS-118 | III | Paroxetine versus Clomipramine and Placebo in the Treatment of Obsessive-Compulsive Disorder |
| MY-059.073/29060/1 | III | A Multicentre, Double-blind Randomised Dose Titration Study Comparing the Efficacy and Safety Profiles of an Increasing Dose Regimen of Oral Paroxetine and Oral Amitriptyline in Adult Patients with Major Depression |
| MY-060/BRL-029060/1 | III | A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression. |
| MY-1001/BRL-029060/1/CPMS 069 | III | A Multicentre, Parallel Group Study to Compare the Efficacy and Tolerability of Paroxetine with Clomipramine in Elderly Patients. |
| MY-1003/BRL-029060/1/CPMS-095 | III | A double-blind comparative study of withdrawal effects following abrupt discontinuation of treatment with paroxetine in low or high dose or imipramine |
| MY-1004/BRL-29060/2/CPMS- 082 | III | A Double-blind Comparative Multicentre Study Comparing Paroxetine 20-40mg/day with Maprotiline 50-150mg/day in Major Depression |
| MY-1005/BRL-029060/1/CPMS-112 | III | A double-blind, multicentre study to compare the effectiveness and tolerance of paroxetine versus fluvoxamine in depressed patients |
| MY1006/BRL029060/2/CPMS094 | III | A Double-Blind Study to Assess The Safety And Tolerability of Paroxetine 60mg And To Compare Two Dosing Regimens |
| MY-1008/BRL-029060/2/CPMS-076 | III | The Effects of Paroxetine Versus Those of Maprotiline and Placebo on Fundamental Cognitive Functions, Perceptual-Motor Skills and Eye Movements in Depressed Patients |
| MY-1010/BRL029060/1/CPMS 079 | III | A double-blind comparative multicentre study comparing paroxetine b.d. (twice daily) with fluoxetine (Prozac®) b.d. (twice daily) in depressed patients |
| MY-1029/BRL-029060/1/CPMS-201 (PAR 201) | III | A Double-Blind, Placebo Controlled Study, to Assess the Efficacy of Paroxetine in the Prevention of Relapse Following Detoxification in Alcoholics |
| MY-1033/BRL-PAR 29060/1/CPMS-.090 and DFG /130/DEN/090 (PAR 090) | III | Paroxetine and Imipramine in the Treatment of Depressive States in Psychiatric Specialist Practice - a Double-Blind Controlled Group Comparison |
| MY-1034/BRL029060/1/CPMS-057 | III | A Double-blind comparative multicentre study of paroxetine plus supportive psychotherapy and psychotherapy alone in the prevention of recurrent suicidal behavior and episodes of intermittent brief depression |
| MY-1035/BRL-029060/1/CPMS-106 | III | A double-blind comparative study of paroxetine and placebo in the treatment of episodes of intermittent brief depression (IBD) |
| MY-1037/BRL-029060/1/CPMS-136 | III | A Double-Blind Study to Assess the Efficacy and Tolerance of a Flexible Dose of Paroxetine Compared with a Flexible Dose of Clomipramine and Placebo in the Treatment of Obsessive Compulsive Disorder. |
| MY-1042/BRL-029060/CPMS-251 | III | A Double-Blind, Randomized Trial of Paroxetine Versus Placebo In Patients With Depression Accompanied by Anxiety |
| MY-1043/BRL-029060/115 | III | A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder. |
| MY-1045/BRL-029060/1 (PAR128) | III | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder |
| MY1047/BRL-029060/1/CPMS-120 | III | A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder |
| MY-1048/BRL-029060/1/CPMS-223 (PAR 223) | III | A Double-Blind, Multicentered, Flexible-Dose Study of Paroxetine, Alprazolam and Placebo in the Treatment of Panic Disorder |
| MY-1050/BRL-029060/1/CPMS-222 (PAR 222) | III | A Double-Blind, Placebo-Controlled, Continuation of Study 29060/120 to Assess the Long Term Safety and Efficacy of Paroxetine in the Treatment of Panic Disorder and its Role in the Prevention of Relapse/Recurrence |
| MY-1053/BRL-029060/1/CPMS-187 (PAR187) | III | A Double-Blind Placebo Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder |
| MY-1053/BRL-029060/CPMS-127 | III | Long-term treatment with paroxetine of outpatients with obsessive-compulsive disorder: An extension of the companion study |
| MY-1055/BRL-029060/1/CPMS-245 (PAR 245) | III | A Double-Blind, Multicentre Study in Primary Care Comparing Paroxetine and Clomipramine in Patients with Depression with Associated Anxiety |
| MY-1056/BRL029060/1/CPMS241 | III | A Double-Blind Study to Compare the Maintenance of Efficacy and Relapse Rates in Patients with Obsessive Compulsive Disorder who Responded to Paroxetine, Clomipramine or Placebo in the Short Term Study 136 |
| MY-1060/BRL 29060/1/CPMS-197 (PAR197) | III | A Double-Blind Comparison of the Efficacy and Tolerability of Paroxetine and Imipiramine in the Treatment of Depression and Behavioural Disturbance Associated with Dementia |
| PAR 024 (MDUK/29060/III/85/024 Shanks) | III | Safety and Efficacy Aspects of a Study to Investigate the Pharmacokinetics of Paroxetine in Younger Depressed Patients. A Study to Investigate the Pharmacokinetics of Paroxetine in Younger Depressed Patients. |
| PAR 029060.289 | III | A Study to Assess the Efficacy and Tolerance of Paroxetine in Patients with Depression by Double-Blind Comparison with Clomipramine |
| PAR 029060.292 | III | A multi-centre study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline |
| PAR 029060-502 | III | A Randomised, Double-blind Study of Paroxetine and Placebo in the Treatment of Social Phobia |
| PAR 03.001 | III | A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 279 MDUK/29060/III/83/12 | III | A Study to Assess the Effectiveness and Tolerance of Paroxetine by Double-Blind Comparison with Placebo and Mianserin |
| PAR 283 (MDUK/29060/III/84/014B) | III | The Short Term Phase of an Open, Long-Term, Safety and Tolerability Study of Paroxetine in Patients Suffering from Depression |
| PAR 286 | III | An investigation of the pharmacokinetics, efficacy, and tolerance of paroxetine in geriatric patients with depression |
| PAR 287 (MDUK/29060/III/86/17C) | III | A Report on the Short-Term Phase of an Open Long-Term Study to Investigate the Safety of Paroxetine in Geriatric Patients |
| PAR 290 (MDF/29060/1727 M) | III | A prospective, randomized, double-blind, multicentre study of the efficacy and tolerance of paroxetine versus clomipramine in the treatment of endogenous depression in the elderly |
| PAR 29060 637 | III | A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with Generalised Anxiety Disorder (GAD) |
| PAR 29060 646 | III | A Study of the Maintained Efficacy and Safety of Paroxetine in Patients with Generalized Anxiety Disorder (GAD) |
| PAR 29060 651 (BRL – 02960) | III | A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). |
| PAR 29060.03.002 | III | A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 29060.03.004 | III | A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 29060.03.005 | III | A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 29060.03.006 | III | A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 29060.04 | III | A Double-Blind Extension of Protocol PAR 03 |
| PAR 29060.065.BE | III | A Double-blind Comparative Study Comparing Paroxetine 20mg-40mg/day with Maprotiline 50mg-150mg/day in Major Depression: Clinical and Biochemical Aspects |
| PAR 29060.228 | III | A Long-Term Extension of a Double-Blind, Placebo -Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder |
| PAR 29060.281 (MDUK/PAR013) | III | A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline in the treatment of depressed patients in General Practice |
| PAR 29060.282 (MDUK 014/Tyrer) | III | A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo using a novel “shifted crossover” design |
| PAR 29060.400 | III | A Double-Blind, Placebo Controlled Study to Investigate the Efficacy, Safety and Tolerability of Paroxetine in Patients with Premenstrual Dysphoric Disorder. |
| PAR 29060/078 | III | A Multicentre Double Blind Study Comparing Paroxetine at a Dose of 20mq Increasing to 30mg Taken in the Morning and Amitriptyline 75mg Increasing to 150mg in Divided Doses in Adult Patients with Major Depressive Disorder |
| PAR 29060/627 | III | A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Posttraumatic Stress Disorder (PTSD) |
| PAR 29060/642 | III | A Randomized, Double-Blind, Placebo Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine in Patients with Generalized Anxiety Disorder |
| PAR 29602.03.003 | III | A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 454 | III | A Randomized, Double-Blind, Fixed Dose Comparison of 20, 40, and 60mg Daily of Paroxetine and Placebo in the Treatment of Generalized Social Phobia. |
| PAR 470 | III | An Extension Trial Comparing Paroxetine and Placebo in the Long Term Treatment of Generalized Social Phobia |
| PAR 595 | III | A Study of the Maintained Efficacy and Safety of Paroxetine versus Placebo in the Long-Term Treatment of Social Phobia |
| PAR 625 | III | An 8-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering From Depression Following Stroke |
| PAR 648 | III | A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Posttraumatic Stress Disorder (PTSD) |
| PAR MDED/29060/III/86/1728M(291) | III | A Multi-Centre Double-Blind Study to Investigate the Safety and Efficacy of Paroxetine in Comparison with Clomipramine in the Treatment of Reactive Depression in Elderly Patients. |
| PAR MDSA/29060/III/86/1182 | III | A Study to Assess the Tolerance of Paroxetine in Short and Long Term Therapy and to Assess the Efficacy and Tolerance in a Subset of Patients in whom Previous Antidepressant Therapy had Failed. An Open Study |
| PAR MDUK 032 | III | A Double Blind Study to Compare the Efficacy and Tolerability of Paroxetine and Amitriptyline in a Multi-Centre General Practice Study in Depressed Patients |
| PAR MY-1009/BRL-029060/2/CPMS-084 | III | A Double Blind Comparative Study of the Effects of Paroxetine and Clomipramine on Cognitive Function in Elderly Patients with Major Depression |
| PAR(BRL)-29060/239 (PAR 239: Continuation Phase) | III | A Randomized, Comparative Study of Paroxetine in the Treatment of Depression as Used in a Clinical Practice Setting |
| PARMDSA/29060/III/86/03/019 | III | Assessment of the efficacy and tolerability of paroxetine by double blind comparison with amitriptyline in depressed patients |
| PARMDUK/29060/III/84/035 | III | A Double-Blind Study to Assess the Efficacy and Tolerance of Paroxetine in Comparison with Amitriptyline in the Treatment of Depression |
| PARMDUK/29060/III/86/042 | III | A Study to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison of Morning and Evening Doses in the Elderly |
| PARMDUK/29060/III/86/046 | III | A Study to Assess the Efficacy and Tolerance of Paroxetine in Elderly Depressed Patients by Double-Blind Comparison with Amitriptyline |
| PARMDUK/29060/III/87/049 | III | A Multi-Centre General Practice Study to Compare the Effectiveness and Tolerability of Paroxetine in Elderly Depressed Patients by Double Blind Comparison with Amitriptyline |
| PCR103124 | III | A Multicentre, Randomized, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine (Paroxetine IR) and Controlled Release Paroxetine (Paroxetine CR) in the Treatment of Major Depression |
| PIR104776 | III | Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) - A Double-blind, Placebo-controlled Study |
| PIR104777 | III | Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD)–A Open-Label, Uncontrolled, Long-term Study– |
| SER-CHN-1 | III | Antidepressant efficacy and safety of paroxetine; a double blind amitriptyline controlled multicenter comparison study in depressive patients. |
| 29060/356 | II | A double-blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability. |
| 29060/356 extension | II | Extension phase for a double-blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability. |
| 6.1.1.1 (Ferrosan) RAD/Paroxetine/C/2 (PAR 258) | II | An Early Clinical Phase II Evaluation of Paroxetine, a New Product and 5-HT Uptake Inhibitor in Patients with Depressive Illness |
| 6112 RAD/Paroxetine/C/3 (PAR 259) | II | Paroxetine, a Selective Serotonin Uptake Inhibitor in the Treatment of Depressive Illness – a Clinical Phase II Study |
| 6121 RAD/Paroxetine/C/4 (PAR 260) | II | The study was designed to compare a 5-hydroxy-tryptamine (5-HT) uptake inhibitor, paroxetine (PAR) with amitriptyline (AMI), in subjects with depression. |
| BRL29060A/856 | II | Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Generalized Anxiety Disorder (GAD) -A Double-blind, Placebo-controlled, Comparative Study- |
| HP/81/126A (PAR 311) | II | Early clinical evaluation of a new antidepressant: An open pilot study of paroxetine 40mg daily |
| HP/81/164A (CPMS 315) | II | Early clinical evaluation of a new antidepressant: An open pilot study of paroxetine 40mg daily |
| HP/84/35A (PAR 313) | II | A study to assess the efficacy and pharmacokinetics of paroxetine in depressed geriatric patients |
| MD/PAR/009 (PAR-276) | II | A double-blind study to investigate the efficacy, safety and tolerability of Paroxetine in the treatment of depression in comparison with placebo |
| MDUK/29060/III/85/040 | II | Clinical aspects of a study to investigate the pharmacokinetics of paroxetine in elderly depressed patients |
| MY-1061/BRL-029060/1-CPMS-327 | II | A double-blind, placebo-controlled, parallel group study of paroxetine in the treatment of dysthymia. |
| NKD10020 | II | A double-blind, double dummy, randomised, parallel group positron emission tomography study to investigate the effects of chronic administration of an oral dose of a GSK New Chemical Entity (NCE), paroxetine 20mg or placebo on regional cerebral blood flow, using the tracer [15O]-water, in subjects affected by social phobia. |
| NKD20006 | II | An 8-week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of a New Chemical Entity (NCE) or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder. |
| NKF100096 | II | A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of a New Chemical Entity (NCE) and Paroxetine in Subjects with Major Depressive Disorder |
| NKF100110 | II | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Forced-Dose Titration Study Evaluating the Efficacy and Safety of a New Chemical Entity (NCE) and Paroxetine in Subjects with Social Anxiety Disorder. |
| NKP102280 | II | A double-blind, double dummy, placebo-controlled, randomised, parallel group positron emission tomography (PET) study to investigate the effects of a 8 week administration of a new compound and Paroxetine in combination or Paroxetine alone (7.5 mg) on regional cerebral blood flow (rCBF) during a Public Speaking test in subjects affected by social anxiety disorder (SAD). |
| PAR 005 | II | A Open-label Long-term Evaluation of Paroxetine in Depressed Outpatients |
| PAR 01.001 | II | A Phase II, Placebo-Controlled, Double-Blind Study of Paroxetine in Depressed Outpatients |
| PAR 06 and PAR 011 | II | Two Combined Multi-Center, Doxepin-Controlled, Double-Blind Studies of Paroxetine in Geriatric Outpatients with Major Depressive Disorder |
| PAR 29060.02.001 | II | A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 29060.02.002 | II | A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 29060.02.003 | II | A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 29060.02.004 | II | A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients |
| PAR 29060.07.001 | II | A Double-Blind Comparison of Paroxetine, Amitriptyline, and Placebo in Inpatients with Major Depressive Disorder with Melancholia |
| PAR 29060.09 | II | A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine |
| PAR 29060.308 (HP/81/74A) | II | Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily with amitriptyline 150mg daily |
| PAR 29060.309 HP/81/162A | II | Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 100mg Daily |
| PAR 29060.310 (HP 81/85A) | II | Early Clinical Evaluation of a New Antidepressant: Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily |
| PAR 29060.314 (HP 82/134) | II | Double Blind Parallel Study Comparing Paroxetine, 30mg Daily, and Amitriptyline, 150mg Daily, in Depressed Patients |
| PAR 29060.316 (HP/82/47A) | II | Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily |
| PAR 29060.317 (HP/82/65A) | II | An early clinical evaluation of a new antidepressant: An open study of paroxetine 40mg o.d. |
| PAR 29060.318 (HP/82/64A) | II | Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily |
| PAR 29060.427 | II | A Multicentre, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Paroxetine (5mg OD Vs 10mg OD Vs 20mg OD) in Patients with Premenstrual Dysphoric Disorder (PMDD). |
| PAR 312 | II | A Phase II Pharmacokinetic Double Blind Study Comparing Paroxetine with Amitriptyline in Depressed Patients |
| PAR 319 (HP/81/148A) | II | Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily, with amitriptyline 150mg daily. |
| PAR DFG/29060/II/85/122 | II | An Interim Report on the Short-term Phase of a Long-term Phase II Open Study to Evaluate Tolerance and Safety of Paroxetine Treatment of Depressive States (a final report was not issued). |
| 29060/ 579 | I | A single dose, four-period crossover study to demonstrate bioequivalence between 25mg controlled-release paroxetine tablets manufactured at Cidra and Crawley. |
| 29060/008 (PAR 08-01) | I | An Open-label, Single-dose, Five-period Crossover Evaluation of the Pharmacokinetic Properties of Paroxetine When Administered by Oral Route |
| 29060/010 (PAR 10-01 / HL 10617) | I | A multiple-dose, steady-state design pharmacokinetic evaluation of the interaction between paroxetine and diazepam |
| 29060/012 (PAR 12-01) | I | A Placebo-controlled, single-dose, five-period crossover evaluation of the pharmacokinetic properties of paroxetine when administered by the oral route |
| 29060/013 (PAR 13-01) | I | A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and cimetidine |
| 29060/014 (PAR14-01) | I | A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and warfarin |
| 29060/015 (PAR 15-01) | I | A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and digoxin |
| 29060/016 (PAR 16-01) | I | A multiple dose, steady-state, cross-over, replicate-sample evaluation of the bioequivalence of a tablet and capsule formulation of paroxetine. |
| 29060/033 (MD/PAR/29060/033) | I | An Examination of Paroxetine and Other Antidepressants Alone and in Combination with Alcohol, on Car Driving and Psychomotor performance. |
| 29060/048 (PN-MD-PAR-048) | I | A study to assess the interaction of paroxetine with digoxin in normal healthy volunteers |
| 29060/051 (MD/PAR/051) | I | A study to compare the bioequivalence of two formulations of paroxetine, a 30 mg tablet and 3 x10 mg capsules |
| 29060/052 (MD/PAR/052) | I | A study to compare the bioequivalence of two formulations of paroxetine: a 30 mg film-coated tablet and a 30 mg caplet |
| 29060/053 (29060/053/001 HINDMARCH) | I | A Double-Blind, Placebo Controlled, Comparative Investigation of the Effects on Psychomotor Performance of Paroxetine and Amitriptyline with or without alcohol in Adult Subjects. |
| 29060/058 (29060/058/001 SALETU) | I | A double-blind, placebo controlled, randomised, single dose, cross-over study comparing the effects on objective and subjective sleep, and awakening and early morning behaviour, of paroxetine 20 mg, 30 mg and 40 mg morning dose, 30 mg evening dose, and fluoxetine 40 mg morning dose in healthy volunteers |
| 29060/075 | I | A Sub-Chronic Comparison of the Effects of Paroxetine Versus those of Amitriptyline and Placebo on Fundamental Perceptual-Motor Skills and Actual Driving Performance |
| 29060/091 | I | A study to investigate the effects of co-administration of three anticonvulsants (carbamazepine, valproate and phenytoin) and paroxetine in epileptic patients |
| 29060/105 (29060/105/HA/001/Sindrup) | I | An open study to investigate the effects of paroxetine (30 mg OD for 14 days) on sparteine oxidasepolymorphism in healthy volunteer subjects. |
| 29060/110 (29060/110/HA/001/LINK) | I | A double-blind, placebo-controlled study to assess the effects of paroxetine on the bleeding time of healthy volunteers |
| 29060/113 (29060/113/HA/001/BROSEN) | I | An open study to investigate the effects of repeated dosing of paroxetine (20 mg od for 20 days) on the pharmacokinetics and metabolism of a single dose of desipramine (100 mg) in healthy volunteer subjects. |
| 29060/121 (HP-1001/BRL-029060/1/CPMS-121) | I | A repeat-dose steady-state crossover evaluation of the bioequivalence of a tablet formulation (20 mg marketing formulation, CIDRA) and a capsule formulation (10 mg CT capsule P47) of paroxetine |
| 29060/125 (PN-HA-001) | I | A double-blind, placebo-controlled study to assess the effects of paroxetine on the bleeding time and prothrombin time of volunteers receiving warfarin therapy |
| 29060/139 (HP/84/39) | I | A study of the pharmacokinetics of paroxetine after single oral doses of BRL 29060A |
| 29060/140 (HP/84/10) | I | Double-blind tolerance study of 30 mg of paroxetine |
| 29060/141 (D85029/29060A/87 and HP/85/33) | I | A comparison of the pharmacokinetics of paroxetine after a single oral dose before and after 30 days of once daily oral administration |
| 29060/142 (HP/84/74) | I | A study to assess the CNS effects of paroxetine and any interaction with the sedative effects of amylobarbitone |
| 29060/143 (HP/86/63) | I | A study to assess the effect of repeat dosing with paroxetine 30 mg once daily on the pharmacokinetics of phenytoin in healthy male volunteers |
| 29060/145 (HP/83/88) | I | Metabolism studies in healthy male subjects following a single oral dose of 14C-BRL 29060A equivalent to 30mg pure free base |
| 29060/146 (HP/84/57) | I | A comparative study of the pharmacokinetics of paroxetine in females who were and were not taking oral contraceptives |
| 29060/147 (HP/84/78) | I | A study of the effects of a single oral dose of paroxetine on systolic time intervals, compared with amitriptyline and placebo |
| 29060/148 (HP 80/99) | I | A study to determine the tolerance, clinical effects and bioavailability of paroxetine in healthy male human volunteers |
| 29060/150 (HP/83/76) | I | A study of the tolerance, pharmacokinetics and absolute bioavailability of BRL 29060A. |
| 29060/151 (HP/83/102/A and HP/83/102) | I | A study to assess the CNS effects of paroxetine (BRL 29060A) and amitriptyline and their interaction with alcohol |
| 29060/152 (HP/85/2) | I | Two-part sequential study of the pharmacokinetic profile of 30 mg tablets of paroxetine after morning and evening administration |
| 29060/153 (HP/85/70 (D85083/29060/88)) | I | An investigation into the pharmacokinetics of BRL 29060 (paroxetine) in patients with impaired renal function |
| 29060/154 (HP/85/3) | I | Two-part sequential study comparing absorption of 30 mg tablets of paroxetine in fasting and non-fasting volunteers |
| 29060/155 (HP/84/54) | I | A study to assess the CNS effects of oxazepam alone and in combination with paroxetine |
| 29060/156 (HP/84/121) | I | A study to assess the CNS effects of paroxetine, and haloperidol and any interaction of paroxetine with the sedative effects of haloperidol |
| 29060/157 (HP/82/14/A) | I | Bioequivalence of four formulations of paroxetine |
| 29060/158 (HP/80/102/A) | I | A placebo controlled, double-blind, 28 day repeat dose tolerance study on paroxetine |
| 29060/159 (HP/82/22/A/1) | I | Double-blind tolerance study of 40 mg of paroxetine. |
| 29060/160 (HP/80/98) | I | Bioavailability of two formulations of paroxetine |
| 29060/161 (HP/82/157) | I | An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man using the lactulose/breath hydrogen method |
| 29060/162 (HP/82/86/A) | I | An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man. |
| 29060/163 (HP/86/78) | I | A study to assess the pharmacokinetics and tolerance of single oral doses and repeat oral doses of paroxetine in healthy elderly subjects and a control population. |
| 29060/164 (HP/87/88) | I | A study to assess the pharmacokinetics and tolerance of single and repeat oral doses of paroxetine in healthy elderly subjects and a young adult control group. |
| 29060/165 (DFG-310) | I | Pharmacokinetics of paroxetine in patients with hepatic dysfunction |
| 29060/166 (DFG 311) | I | Study to elucidate any interaction between four anticonvulsants and paroxetine |
| 29060/167 (HP/83/81/A) | I | An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man using the lactulose/breath hydrogen method |
| 29060/168 (HPG 25/83) | I | An open two-part crossover study in healthy male volunteers to examine the effects of co-administration of Aludrox on the pharmacokinetics of BRL 29060 (paroxetine) after single oral dose of 30 mg BRL 29060 |
| 29060/169 (HPG 34/84) | I | Pharmacokinetics of paroxetine before and after an eventual liver enzyme induction caused by multiple oral dosing of phenobarbitone to healthy male volunteers |
| 29060/170 (HPG 19/84) | I | A single-blind study to examine the pharmacokinetics and tolerance of paroxetine and propranolol and any interaction between them under steady state conditions |
| 29060/171 (HPG1-10/85) | I | Pharmacokinetics and effects of tranylcypromine and paroxetine and any interaction between them in healthy male volunteers |